MARIJN E. DEKKERS - 31 Dec 2022 Form 5 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
CERE
Transactions as of
31 Dec 2022
Transactions value $
$0
Form type
5
Filing time
14 Feb 2023, 16:52:12 UTC
Previous filing
07 Nov 2022
Next filing
09 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Gift $0 -14.3K -33.33% $0.00 28.5K 21 Dec 2022 Direct
holding CERE Common Stock 602K 31 Dec 2022 See footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held directly and indirectly by Novalis LifeSciences Investments I, L.P., or Novalis LifeSciences. Marijn Dekkers, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.